9月4日，第十七届中国生物产业大会在汉开幕。本届大会由中国生物工程学会等17家国家级学（协）会与中国科学报社共同主办，是 我国生物产业领域规模最大、影响最广的大型专业活动。 在光谷科技会展中心，大会集中展出了国内外生物产业基地、科研机构及龙头企业的最新成果，多项源自武汉、技术领先乃至"全球首 个"的重大创新产品集中亮相。 武汉禾元生物科技股份有限公司（以下简称"禾元生物"）展出了全球首创的植物源重组人血清白蛋白注射液奥福民®。一周多前，作 为全球首个"稻米造血"一类新药，该药品正式用于患者治疗，改写了人血清白蛋白依赖血浆提取的历史。 同济医院展示的光学脑机接口，在全球首创融合脑电图和近红外光谱多模态传感系统，主要用于脑出血康复，预计明年可上市。 中国生物产业大会现场。主办方供图 会上发布的《中国生物经济发展报告2025》显示，我国生物经济产业规模稳居全球第一，并呈现持续增长态势，在生物药在研品种、 脑机接口、高精度数字切片等前沿领域已实现"并跑"甚至"领跑"。 武汉自2018年起成为中国生物产业大会永久举办地之一。目前，武汉已形成覆盖创新研发、规模生产、临床运用全链条的生物医药产 业集群，产业规模突破5500 ...

Core Insights - China has become the second largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report highlights China's leading position in areas such as research and development of biopharmaceuticals, brain-computer interfaces, and high-precision digital slicing [1] Industry Developments - In 2024, the National Medical Products Administration of China approved 93 new drugs, marking a five-year high, with China ranking second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, setting a new historical record [2] - China published over 20,000 SCI papers in the medical equipment field in 2024, leading the world in research output [2] - The biopharmaceutical industry in China accounts for over 30% of global innovative drugs, research pipelines, and newly listed drugs [2] Economic Impact - The value of bio-based materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] - China has established 23 biopharmaceutical industry bases, leading globally in the number of biotechnology patent applications and R&D personnel [2] International Collaboration - The conference attracted Cuba's largest state-owned pharmaceutical group, highlighting successful collaboration in biotechnology between China and Cuba [3] - Jointly developed drugs, such as the EGFR monoclonal antibody for cancer treatment, have benefited over 50,000 Chinese patients [3]

Group 1 - The 17th China Bio-Industry Conference highlighted that China has become the second-largest biopharmaceutical market globally, meeting domestic demand while gradually participating in international market competition [1] - The report indicates that China is in a leading position in areas such as biopharmaceuticals under research, brain-machine interfaces, and high-precision digital slicing [1] - The global focus on biomanufacturing and circular economy strategies is increasing, with significant funding for gene and cell engineering research, biomass utilization, and the development of bioproducts [1] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and ranks second globally in the number of drugs under research [2] - Four Chinese companies made it to the top 25 global pharmaceutical companies in terms of R&D pipeline scale, marking a historic achievement [2] - China leads the world in the number of SCI papers published in medical equipment, with over 20,000 papers in 2024, showcasing strong research resources and innovation capabilities [2] Group 3 - The National Development and Reform Commission reported that China has established 23 biomanufacturing bases, leading in biotechnology patent applications and R&D personnel [2] - The biopharmaceutical industry in China ranks second globally, with innovative drugs, research pipelines, and newly approved drugs accounting for over 30% of the global total [2] - The value of biobased materials and chemicals has surpassed 1 trillion yuan, with the contribution of the bio-economy to GDP exceeding 7% [2] Group 4 - The conference featured over 200 renowned institutions and companies, showcasing more than 1,000 products, including several global firsts [2] - Notable innovations included a multimodal sensing system for brain rehabilitation and a world-first 5.0T whole-body MRI system [3] - The collaboration between China and Cuba in biotechnology was highlighted as a successful partnership, with joint research and production benefiting both nations [3]

Core Insights - The 17th China Bio-Industry Conference was held in Wuhan, showcasing China's strength and innovation in the bio-industry through policy interpretation, technical discussions, resource collaboration, international cooperation, and achievement transformation [1][2] - The conference highlighted China's rapid advancement in four key areas: biomedicine, bio-agriculture, biomass substitution, and bio-safety, with a focus on enhancing global influence and connectivity in the bio-economy [2] Industry Overview - The conference featured the release of the "China Bio-Economy Development Report 2025," which indicates that China is accelerating its position in the global value chain, leading in biotech patent applications and R&D personnel, and ranking second globally in biomedicine market size [1] - Approximately 30% of the world's innovative drugs under research are from China, with notable advancements in CAR-T cell therapy and brain-machine interfaces [1] Regional Development - Wuhan has developed a comprehensive biomedicine industry cluster centered around the Optics Valley Bio-City, covering the entire chain from innovation research and large-scale production to clinical applications, with an industry scale exceeding 550 billion RMB [2]

Group 1 - China ranks second globally in the number of CAR-T clinical research centers, with 388 centers, reflecting a 60% increase from 2020 [2] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with over 30% of new drug approvals and research pipelines globally [1][3] - The number of in-development drugs in China is second globally, with a narrowing gap compared to the United States [3] Group 2 - The establishment of 23 biomanufacturing bases across China indicates a robust growth trajectory in the biomanufacturing sector [1] - The "National Innovation Drug Insight System" aims to enhance the efficiency of innovative drug development by integrating data across the R&D and approval chain [4] - The biomanufacturing industry is projected to grow significantly, with the global bio-based chemicals market expected to reach $125.23 billion by 2029 [5][6] Group 3 - China leads globally in the number of medical device patent applications, accounting for nearly 70% of the total [3] - The biomanufacturing sector is expected to become a key driver of economic growth, with significant advancements in synthetic biology and gene editing technologies [7] - The agricultural biotechnology market in China is projected to reduce production costs and pesticide usage, with transgenic crops entering the industrial demonstration phase [6]

Group 1: Overview of China's Biomanufacturing Industry - The value added by the biomanufacturing sector accounts for over 7% of China's GDP [4] - China ranks second globally in the number of CAR-T cell therapy research centers and the number of biopharmaceuticals under research [1][4] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with a significant number of innovative drugs and research pipelines [5] Group 2: Innovations and Developments - The "National Innovation Drug Insight System" was launched to enhance the efficiency of innovative drug development and address industry challenges [7] - The Hubei Pathology Big Database has reached 170,000 high-precision digital slices, positioning it as the second largest globally [6] - The global CAR-T clinical research centers have increased by 60% from 2020 to 2024, with China contributing 388 centers [5] Group 3: Market Growth and Future Projections - The global biomanufacturing market is projected to grow significantly, with the biobased chemicals market expected to reach $125.23 billion by 2029 [8] - China's biomanufacturing sector is positioned as a new engine for economic growth, supported by national policies and strategic planning [8] - The biotechnological innovations in agriculture, such as genetically modified crops, are set to enter the industrialization demonstration phase in 2024 [9]

"展"的板块。本届展会采取"线上+线下"双线融合展示模式，线下展厅设在中国光谷科技会展中心。 10000平方米大型专业展览，规划综合形象展区、生物制造体验展和未来发展展区三大板块，系统展示 国内外生物产业基地、科研机构及头部企业的最新成果、创新实践。 本次展会致力于打造国际级的"生物产业风向标"，让公众一站式领略中国生物产业的发展水平和创新活 力。展会现场，武汉禾元生物、高科医疗器械园、嫦娥生物等多家龙头企业纷纷亮相，200余家企业和 机构展出千余件展品。 "赛"的板块。本届大会同步举行"2025生物制造创新创业大赛"总决赛，举行中国生物产业大会2025生物 制造创新创业大赛颁奖及创新力榜单发布仪式。 （原标题：第十七届中国生物产业大会在汉开幕） 经济观察网 程久龙 实习生 刘轩宇 9月4日上午，第十七届中国生物产业大会在武汉·中国光谷科技会展 中心隆重开幕。本届大会紧扣国家"十四五"生物经济发展规划、"十五五"前瞻布局，以"生物科技赋能 未来·生物制造重塑世界"为主题展开，集中展示了我国生物科技与生物制造领域的最新成果、发展趋 势，凸显了中国生物经济的高质量发展和新质生产力的提升，同时也为国际间开展生物产业 ...

Core Viewpoint - Zhejiang Qianjiang Biochemical Co., Ltd. reported a decrease in revenue but an increase in net profit for the first half of 2025, indicating a shift in financial dynamics due to changes in subsidiary control and operational adjustments [2][17]. Financial Summary - The company's operating income for the first half of 2025 was CNY 779.54 million, a decrease of 9.64% compared to the same period last year [2]. - Total profit reached CNY 128.77 million, an increase of 45.64% year-on-year [2]. - Net profit attributable to shareholders was CNY 107.12 million, up 30.24% from the previous year [2]. - The net cash flow from operating activities surged by 1,298.31%, amounting to CNY 105.87 million, primarily due to increased cash inflow from engineering sales [2]. - Total assets decreased by 7.08% to CNY 7.02 billion, while net assets attributable to shareholders increased by 3.19% to CNY 3.38 billion [2]. Business Segments Overview Water and Environmental Protection - The water and environmental protection segment generated CNY 632 million in revenue, accounting for 81.03% of total revenue, but saw an 11.85% decline year-on-year [17]. - The company operates multiple wastewater treatment plants and has significant market presence in regions such as Jiangsu, Gansu, and Inner Mongolia [5][11]. - The company aims to enhance its market position by expanding its service offerings and participating in regional water projects [11][19]. Biological Manufacturing - The biological manufacturing segment achieved revenue of CNY 141 million, representing an increase of 6.82% compared to the previous year [17]. - The market for biological pesticides, particularly microbial and plant-derived products, is expected to grow significantly, with a projected compound annual growth rate exceeding 25% [8]. - The company is focusing on product innovation and expanding its market reach, particularly in the domestic rice seed production market [17][10]. Industry Trends - The water and environmental protection industry is transitioning towards a green and low-carbon economy, with policies aimed at reducing pollution and enhancing resource utilization [4][5]. - The biological pesticide market is experiencing a shift towards environmentally friendly products, driven by regulatory changes and increasing demand for sustainable agricultural practices [8][9]. - The overall agricultural chemical market is facing challenges such as overcapacity and intense competition, leading to price declines for many pesticide products [16].

Core Viewpoint - Zanyu Technology (002637) reported a significant revenue increase of 41.71% year-on-year, reaching 6.553 billion yuan in the first half of 2025, with a net profit of 97 million yuan, reflecting the company's robust growth amid a complex global economic environment [1] Group 1: Business Performance - The company's main business segments include surfactants, fatty chemical products, and OEM/ODM personal care products, with over 97% of revenue derived from these core areas [1] - In the surfactant industry, the total production is projected to decline by 2.8% in 2024, while anionic surfactants are expected to see sales growth of 10.5% and 14.0% respectively [1] - Zanyu's market share in key products AES and LAS exceeds 70%, solidifying its leading position in the domestic market [1] Group 2: Industry Trends - The fatty chemical products sector is transitioning towards differentiation and high-end products, with a projected annual growth rate of 5% to 8% for major products like fatty acids and alcohols in 2024 [2] - The demand for green and low-carbon fatty chemical products is steadily increasing, supported by national policies [2] - The synthetic detergent production in China is expected to reach 12.246 million tons in 2024, marking a 14.3% year-on-year increase, providing ample space for the OEM business [2] Group 3: Strategic Initiatives - The company has established a comprehensive model integrating surfactant production and personal care product processing, with an OEM/ODM capacity of 1.1 million tons [3] - Zanyu has strategically positioned production bases across multiple regions, including Indonesia, to enhance supply chain efficiency and cost control [3] - The company invested 54.9981 million yuan in R&D during the first half of 2025, a 20.37% increase, focusing on new product development and process optimization [3] Group 4: Corporate Responsibility and Future Outlook - Zanyu actively engages in social responsibility initiatives, including environmental protection projects and compliance with national environmental policies [4] - The company aims to optimize product structure, enhance high-value product ratios, and strengthen supply chain resilience while continuing to innovate [4] - Zanyu is well-positioned to lead high-quality industry development through its comprehensive value chain advantages amid ongoing industry consolidation and upgrades [4]

Group 1 - The Ministry of Industry and Information Technology and the National Health Commission of China have launched a notice to collect innovative applications of biological manufacturing technologies in the food processing sector, focusing on areas such as food raw materials, food additives, and food and beverage manufacturing [1] - The application directions should align with the goal of building a diversified food supply system and have significant promotional value for industry development, referencing safety evaluation requirements for genetically modified microorganisms [1] - Specific conditions for the applications include: products must be developed domestically and have entered small-scale trial production or mass production; products must have sufficient research results proving their safety or have been approved in other countries for food processing; and products must meet the criteria for "three new foods" in China but have not yet been approved [1] Group 2 - Huazhong Securities has released a research report indicating that frontier research in life sciences remains active, with a global biotechnology revolution accelerating its integration into economic and social development, providing new solutions for major challenges such as health, climate change, resource security, and food security [2] - The report suggests that the biological economy is emerging as a trillion-dollar sector, highlighting the potential for significant investment opportunities in this field [2]